Compare DuPont de Nemours Inc (DD) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DuPont de Nemours Inc vs TG Therapeutics Inc — how do they compare? DuPont de Nemours Inc trades at $130 (market cap $17.89B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: DuPont de Nemours Inc is far larger — about 2.2× TG Therapeutics Inc's market cap, and DuPont de Nemours Inc pays a 1.81% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold DuPont de Nemours Inc for 89 Days and TG Therapeutics Inc for 16 Days on average.
| DD | TGTX | |
|---|---|---|
Market Cap | $17.89B | $8.16B |
Volume | 816,409 | 1,735,121 |
Sector | Basic Materials | Health |
52-Week High | $154.59 | $59.06 |
52-Week Low | $92.49 | $26.94 |
Typical Hold Time | 89 Days | 16 Days |
Enterprise Value | $19.28B | $8.37B |
Dividend Yield | 1.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DuPont (DD) trades at $132.48, up 1.07% today, showing strong recent earnings beats but facing profitability challenges with a net margin of 0.79%. Technical indicators are neutral, with the stock trading near key resistance at $132. Recent news highlights innovation in sustainable materials and legal settlements over PFAS claims. The company's cash flow has been negative in recent years, though 2026 projections show improvement.
The outlook is mixed: analyst consensus is bullish (58.5% buy ratings) with a high price target of $172, but the current price exceeds the consensus target of $95. Key risks include ongoing legal liabilities, volatile earnings, and high debt. Revenue growth and margin expansion in healthcare and water technologies present opportunities, but investors should weigh these against significant financial and legal headwinds.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
